CW January 2005
Volume 14Issue Number 1 January 2005 ISSN 10593802 Breast Cancer-Treatment Bone Loss Countered with Zoledronic AcidBreast cancer treatment-induced bone loss (CTIBL) increases with treatment duration and is more severe when anastrozole (ANA)(Arimidex, AstraZeneca) is used in combination with goserelin. Zoledronic acid (Zometa, Novartis), a bisphosphonate, effectively counteracts that bone loss, according to study results presented at the 27th Annual San Antonio Breast Cancer Symposium.
Go to Previous Page Go to Next Page Source & Additional Reading Austrian Breast and Colorectal Cancer Study Group, 27th Annual San Antonio Breast Cancer Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
